Researchers have developed immunoprofiles for an emerging disease with a mortality rate as high as 27%
Largest series shows marker sensitive, highly specific
Turn to 8th edition for better correlation
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy